BR100 Increased By (0.01%)
BR30 Decreased By (-1.15%)
KSE100 Increased By (0.09%)
KSE30 Decreased By (-0.05%)
AGHA 6.02 Decreased By ▼ -0.03 (-0.5%)
BECO 3.81 Decreased By ▼ -0.02 (-0.52%)
BML 56.44 Decreased By ▼ -1.89 (-3.24%)
BOP 28.10 Decreased By ▼ -0.25 (-0.88%)
CNERGY 12.28 Decreased By ▼ -1.36 (-9.97%)
CSIL 5.29 Increased By ▲ 0.08 (1.54%)
FCCL 53.81 Increased By ▲ 1.53 (2.93%)
FFL 12.80 Decreased By ▼ -0.10 (-0.78%)
FNEL 1.12 Decreased By ▼ -0.01 (-0.88%)
KEL 5.64 Decreased By ▼ -0.15 (-2.59%)
KOSM 5.38 Decreased By ▼ -0.13 (-2.36%)
LOTCHEM 23.55 Decreased By ▼ -0.34 (-1.42%)
MLCF 91.96 Increased By ▲ 1.45 (1.6%)
NBP 162.24 Increased By ▲ 2.52 (1.58%)
NCPL 48.91 Decreased By ▼ -0.69 (-1.39%)
NPL 50.51 Decreased By ▼ -1.29 (-2.49%)
OGDC 301.68 Decreased By ▼ -5.10 (-1.66%)
PACE 9.13 Decreased By ▼ -0.02 (-0.22%)
PAEL 31.81 Decreased By ▼ -0.52 (-1.61%)
PIBTL 12.78 Decreased By ▼ -0.15 (-1.16%)
PPL 212.06 Decreased By ▼ -1.87 (-0.87%)
PRL 87.26 Decreased By ▼ -9.70 (-10%)
PTC 43.96 Decreased By ▼ -1.23 (-2.72%)
SSGC 22.86 Increased By ▲ 0.33 (1.46%)
TBL 8.91 Decreased By ▼ -0.11 (-1.22%)
TELE 6.44 Decreased By ▼ -0.28 (-4.17%)
TPL 24.09 Decreased By ▼ -1.82 (-7.02%)
TPLP 12.16 Decreased By ▼ -0.44 (-3.49%)
TREET 23.50 Increased By ▲ 0.04 (0.17%)
TRG 51.87 Decreased By ▼ -0.09 (-0.17%)
World

EU willing to discuss COVID-19 vaccine patent waiver

  • "The EU is also ready to discuss any proposals that addresses the crisis in an effective and pragmatic manner," she said in a speech to the European University Institute in Florence.
Published Updated
By

BRUSSELS: The European Union is willing to discuss a proposal, now backed by the United States, to waive intellectual property rights for COVID-19 vaccines, European Commission president Ursula von der Leyen said on Thursday.

"The EU is also ready to discuss any proposals that addresses the crisis in an effective and pragmatic manner," she said in a speech to the European University Institute in Florence.

"That's why we are ready to discuss how the US proposal for a waiver on intellectual property protections for COVID-19 vaccines could help achieve that objective."

Comments

Comments are closed for this article.